Adding atezolizumab to adjuvant chemotherapy for stage II and III triple-negative breast cancer is unlikely to improve efficacy
Adding atezolizumab to adjuvant chemotherapy for stage II and III triple-negative breast cancer is unlikely to improve efficacy
CDK-4/6 inhibitors with endocrine treatment for metastatic breast cancer
Preoperative endocrine therapy in premenopausal women leads to sparing chemotherapy in additional patients
Significant clinical benefits observed with revumenib monotherapy in relapsed/refractory KMT2Ar acute leukaemia
Ide-cell enhances health-related quality of life for refractory multiple myeloma
Zanidatamab, palbociclib and fulvestrant show positive results in treating HER2+/HR+ mBC
Toripalimab and metronomic chemotherapy show efficacy in treating in HER2-negative metastatic breast cancer
BrECADD combined with PET2-guided treatment sets a new benchmark for the treatment of newly diagnosed advanced-stage cHL
Ponatinib is superior to imatinib in combination with chemotherapy for newly diagnosed Ph+ ALL
Cancer care in Needle Hospital, Hargeisa, Somaliland
Relapsed refractory multiple myeloma
First-line chemotherapy with atezolizumab and bevacizumab significantly improves survival for R/M cervical cancer